Skip to main content

Theseus Pharmaceuticals Inc(THRX-Q)
NASDAQ

Today's Change
Delayed Last Update

Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results

PR Newswire - Thu Mar 9, 2023

THE-630 phase 1 preliminary dose-escalation data anticipated in Q2 2023; additional data including dose levels projected preclinically to provide pan-variant KIT coverage planned for Q4 2023

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe